T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) is an immune checkpoint inhibitor that suppresses immune function. Our study investigated TIM-3 transcriptomic expression in 514 cancers and found high expression in 90 (17.5%) tumors. Pancreatic cancer showed the highest expression of TIM-3.

Comprehensive genomic profiling (CGP) plays a key role in precision medicine as it enables simultaneous identification of multiple tumor biomarkers to guide cancer diagnosis, therapy selection, and prognostication. Thus, tissue stewardship for successful CGP is critical.

Manual scraping from formalin-fixed paraffin-embedded (FFPE) slides is inefficient and prone to error. The Xyall Tissector HT system automates tissue dissection, successfully scraping regions of interest (ROIs) with minimal deviation. It ensures consistent DNA/RNA quantity and quality, surpassing manual methods.

Library preparation for next-generation sequencing (NGS) is complex, laborious, and includes multiple repetitive steps, making these workflows suitable for automated solutions.

This study reports a prespecified exploratory biomarker analysis of the Phase III PARAGIGM trial, which demonstrated increased overall survival with first-line anti-EGFR (panitumumab) therapy as compared with anti-vascular endothelial growth factor (bevacizumab) therapy in combination with modified FOLFOX6 in RAS wild-type metastatic colorectal ca

Cancer-testis antigens (CTAs) are tumor antigens normally expressed in the testes but are aberrantly expressed in several cancers. Overexpression of CTAs has been shown to drive cancer metastasis. R.J.